Our findings regarding the SLE patients are slightly different from previous studies [29,30,31,32], which demonstrated expansion of the effector and senescent CD4+ T- cell subpopulations in SLE patients compared to healthy controls; nevertheless, they emphasize their superiority mainly in patients with active disease, or those with metabolic syndrome. This evidence concerns the gene CD4 and metabolic syndrome.